Disparate changes in plasma and tissue pentosidine levels after kidney and kidney-pancreas transplantation

Clinical Transplantation

Volumn 10, Issue 6 I, 1996, Pages 568-573

  Hricik, Donald E ^a   Wu, Yu Ching ^a   Schulak, James A ^a   Friedlander, Miriam A ^a  

^a UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

Author keywords

Advanced glycation end products; Kidney transplantation; Pancreas transplantation; Pentosidine

Indexed keywords

COLLAGEN; PENTOSIDINE; PLASMA PROTEIN; SUGAR; UNCLASSIFIED DRUG;

ADULT; ARTICLE; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; HYPERGLYCEMIA; KIDNEY FAILURE; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; PANCREAS TRANSPLANTATION; PRIORITY JOURNAL; SKIN;

ADULT; AGE FACTORS; ANALYSIS OF VARIANCE; ARGININE; BLOOD PROTEINS; COLLAGEN; CROSS-LINKING REAGENTS; DIABETES MELLITUS; FEMALE; FOLLOW-UP STUDIES; GLOMERULAR FILTRATION RATE; HUMANS; HYPERGLYCEMIA; KIDNEY FAILURE, CHRONIC; KIDNEY TRANSPLANTATION; LINEAR MODELS; LYSINE; MALE; MIDDLE AGED; PANCREAS TRANSPLANTATION; PERITONEAL DIALYSIS; RENAL DIALYSIS; SEX FACTORS; SKIN;

EID: 0030448322     PISSN: 09020063     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. BROWNLEE M. Glycation and diabetic complications. Diabetes 1994: 43: 836.
2. MONNIER VM, KOHN RR, CERAMI A. Accelerated age-related browning of collagen in diabetes mellitus. Proc Natl Acad Sci USA 1984: 81: 583.
3. SELL DR, MONNIER VM. Structure elucidation of a senescence cross-link from human extracellular matrix. Implication of pentoses in the aging process. J Biol Chem 1989: 264: 21597.
4. SELL DR, MONNIER VM. Isolation, purification and partial characterization of novel fluorescence from aging human insoluble collagen-rich tissue. Connect Tissue Res 1989: 19: 77.
5. GRANDHEE SK, MONNIER VM. Mechanism of formation of the Maillard protein cross-link pentosidine. Glucose, fructose, and ascorbate as pentosidine precursors. J Biol Chem 1991: 266: 11649.
6. SELL DR, MONNIER VM. End-stage renal disease and diabetes catalyze the formation of a pentose-derived cross-link from aging human collagen. J Clin Invest 1990: 85: 380.
7. MAKITA Z, RADOFF S, RAYFIELD EJ, et al. Advanced glycosylation end products in patients with diabetic nephropathy. N Engl J Med 1991: 325: 836.
8. HRICIK DE, SCHULAK JA, SELL DR, FOGARTY JF, MONNIER VM. Effects of kidney or kidney-pancreas transplantation on plasma pentosidine. Kidney Int 1993: 43: 398.
9. ODETTI P, FOGARTY J, SELL DR, MONNIER VM. Chromatographic quantitation of plasma and erythrocyte pentosidine in diabetic and uremic subjects. Diabetes 1992: 41: 153.
10. FRIEDLANDER MA, WU YC, MONNIER VM, SCHULAK JA, Hricik DE. Influence of dialysis modality on plasma and tissue concentrations of pentosidine in patients with end-stage renal disease. Am J Kidney Dis 1995: 25: 445.
11. NORUSIS MJ. SPSS/PC. Chicago: SPSS, Inc., 1984.
12. BROWNLEE M, VLASSARA H, CERAMI A. Nonenzymatic glycosylation and the pathogenesis of diabetic complications. Ann Intern Med 1984: 101: 527.
13. VLASSARA H, BROWNLEE M, CERAMI A. High-affinity receptor-mediated uptake and degradation of glucose-modified proteins: a potential mechanism for the removal of senescent macromolecules. Proc Natl Acad Sci USA 1985: 263: 5588.
14. RADOFF S, VLASSARA H, CERAMI A. Characterization of a solubilized cell surface binding protein on macrophages specific for proteins modified nonenzymatically by advanced glycosylation end products. Arch Biochem Biophys 1988: 263: 418.
15. DYER DG, BLACKLEDGE JA, THORPE SR, BAYNES JW. Formation of pentosidine during nonenzymatic browning of proteins by glucose. Identification of glucose and other carbohydrates as possible precursors of pentosidine in vivo. J Biol Chem 1991: 266: 11654.
16. BAYNES JW. Role of oxidative stress in development of complications in diabetes. Diabetes 1991: 40: 405.
17. YAN SD, SCHMIDT AM, ANDERSON GM, et al. Enhanced cellular oxidant stress by the interaction of advanced glycation end products with their receptors/binding proteins. J Biol Chem 1994: 269: 9889.
18. LEE WK, AKYOL M, SHAW S, DOMINICZAK MH, BRIGGS JD. Kidney transplantation decreases the tissue level of advanced glycosylation end-products. Nephrol Dial Transpl 1995: 10: 103.
19. VLASSARA H, BROWNLEE M, MANOGUE KR, DINARELLO CA, PASAGIAN A. Cachectin/TNF and IL-I induced by glucose-modified proteins: role in normal tissue remodelling. Science 1988: 240: 1546.
20. BUCALA R, TRACEY KJ, CERAMI A. Advanced glycosylation products quench nitric oxide and mediate defective endothelium-dependent vasodilation in experimental diabetes. J Clin Invest 1991: 87: 432.
21. ESPOSITO C, GERLACH H, BRETT J, STERN D, VLASSARA H. Endothelial receptor-mediated binding of glucose-modified albumin is associated with increased monolayer permeability and modulation of cell surface coagulant properties. J Exp Med 1989: 179: 1387.
22. VLASSARA H. Serum advanced glycosylation end products: a new class of uremic toxins? Blood Purif 1994: 12: 54.